Related Experiment Video
Updated: Jan 16, 2026
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Psychiatric disorders associated with newer antiseizure medications: A real-world disproportionality analysis of FDA
Jiahao Li1, Rujia Zhong2, Feng Zhang3
1Department of Molecular Neurobiology, Groningen Institute of Evolutionary Life Science (GELIFES), University of Groningen 9747 AG Groningen, the Netherlands.
Background:
Antiseizure medications (ASMs), particularly newer agents such as levetiracetam, topiramate, and perampanel, are fundamental in treating epilepsy and related disorders. Our study aims to analyze the psychiatric safety profiles of newer ASMs.
Research Design And Methods:
The data were extracted from the US FDA Adverse Event Reporting System (FAERS) database from 2004Q1 to 2024Q2. The analysis focused on the clinical characteristics, the ranking of adverse reactions, the time-to-onset, and the severity proportion of newer ASMs-related psychiatric disorders.
Results:
Disproportionality analysis highlighted a significant association between newer ASMs and psychiatric adverse events (AEs), with drugs like perampanel and levetiracetam showing notably high risks for severe psychiatric outcomes such as aggression, suicidal ideation, and psychosis. The median time-to-onset of psychiatric AEs was 33 days, with a substantial proportion (46.4 %) occurring within the first 30 days of treatment. Among all ASMs, perampanel has the highest severe proportion of ASM-associated psychiatric disorders at 51.5 %.
Conclusions:
Our findings underscore a significant link between the use of newer ASMs and the risk of developing psychiatric disorders, suggesting the need for careful psychiatric assessment and monitoring when prescribing these medications.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...